Krall continued, "SDC is unique because of its superior efficacy and its low toxicity, while providing residual protection without promoting bacterial resistance. As pressure mounts in the US and abroad for environmentally sound technologies to address global health concerns, we feel that PURE is well-positioned to supply SDC as a prime solution to multiple markets including household, institutional, healthcare, personal care, textiles, industrial fluids, water treatment, agriculture and food processing."
During the quarter, the United States Patent and Trademark Office issued patent number 7,435,438, which covers PURE's process for treating consumable food products with silver dihydrogen citrate (SDC) to reduce or eliminate microbial contamination. The new patent expands the scope of protection of PURE's core technology patent, US Patent 6,197,814, covering the composition and method of making of PURE's silver dihydrogen citrate (SDC) antimicrobial.
Subsequent to the quarter's end, in November PURE announced a new agreement with Ciba (SWX: CIBN) to market and sell PURE's silver dihydrogen citrate antimicrobial as a natural preservative and biocide in the personal care, household, and industrial markets worldwide. In the personal care market, PURE granted Ciba exclusive marketing rights for SDC under the trade name Ciba(R) TINOSAN(R) SDC.
"We continue to work on a number of important alliances and major market opportunities and expect that these efforts will be successful on an ongoing basis," Krall concluded.
About PURE Bioscience
PURE Bioscience develops and markets technology-based bioscienc
|SOURCE PURE Bioscience|
Copyright©2008 PR Newswire.
All rights reserved